Scholarlink

<p>Colorectal cancer (CRC), the third most common malignancy worldwide, remains difficult to treat in advanced stages. Tumor Treating Fields (TTFields) are a non-invasive therapy that disrupts mitosis via intermediate frequency alternating electric fields, already clinically approved and widely implemented in the treatment of glioblastoma. This study is the first to systematically evaluate the therapeutic efficacy of TTFields in a large panel of low-passage CRC cell lines, representing diverse biological backgrounds. Our results demonstrate that TTFields exert antitumor effects through multiple mechanisms, including microtubule disruption, metabolic stress induction, mitotic aberrations, DNA damage, and activation of apoptotic pathways. Transcriptomic profiling, targeted sequencing, and weighted gene co-expression network analysis identified N-acetylated alpha-linked acidic dipeptidase-like 1 (<i>NAALADL1</i>) as a resistance-associated gene. NAALADL1 proved significantly upregulated in resistant lines, and its knockdown via shRNA sensitized cells to TTFields. Mechanistically, NAALADL1 depletion destabilized microtubules and induced G2/M arrest, enhancing TTFields efficacy. Virtual screening further identified Lumacaftor and Bestatin as candidate NAALADL1 inhibitors, which synergized with TTFields to suppress CRC cell growth. These findings highlight significant heterogeneity in CRC cell line responses to TTFields and identify NAALADL1 as a key modulator of resistance, suggesting its potential as a target for improving TTFields-based therapies in CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NAALADL1 modulates cellular resistance to Tumor Treating Fields in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Zhaoran Su,
  • Menglan Liu,
  • Mathias Krohn,
  • Jasmin Ostermann,
  • Sandra Schwarz,
  • Olga Hahn,
  • Marcus Frank,
  • Timo Gemoll,
  • Clemens Schafmayer,
  • Michael Linnebacher

摘要

Colorectal cancer (CRC), the third most common malignancy worldwide, remains difficult to treat in advanced stages. Tumor Treating Fields (TTFields) are a non-invasive therapy that disrupts mitosis via intermediate frequency alternating electric fields, already clinically approved and widely implemented in the treatment of glioblastoma. This study is the first to systematically evaluate the therapeutic efficacy of TTFields in a large panel of low-passage CRC cell lines, representing diverse biological backgrounds. Our results demonstrate that TTFields exert antitumor effects through multiple mechanisms, including microtubule disruption, metabolic stress induction, mitotic aberrations, DNA damage, and activation of apoptotic pathways. Transcriptomic profiling, targeted sequencing, and weighted gene co-expression network analysis identified N-acetylated alpha-linked acidic dipeptidase-like 1 (NAALADL1) as a resistance-associated gene. NAALADL1 proved significantly upregulated in resistant lines, and its knockdown via shRNA sensitized cells to TTFields. Mechanistically, NAALADL1 depletion destabilized microtubules and induced G2/M arrest, enhancing TTFields efficacy. Virtual screening further identified Lumacaftor and Bestatin as candidate NAALADL1 inhibitors, which synergized with TTFields to suppress CRC cell growth. These findings highlight significant heterogeneity in CRC cell line responses to TTFields and identify NAALADL1 as a key modulator of resistance, suggesting its potential as a target for improving TTFields-based therapies in CRC.